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Introduction
Renal cell carcinoma (RCC) is the most lethal of  urologic malignancies, accounting for an estimated 65,340 
new cases and 14,970 deaths in the United States in 2018 (1). Surgical resection for clinically localized 
disease remains the mainstay for curative intervention. However, approximately 20%–40% of  patients will 
develop disease recurrence, and two-thirds of  these patients will have their disease recur within the first 
year after nephrectomy (2). Although sunitinib was approved in the adjuvant setting in the United States 
based on recurrence free survival (3), in the neoadjuvant setting, no therapies have been approved (4). 
BACKGROUND. Surgery remains the frontline therapy for patients with localized clear cell renal cell 
carcinoma (ccRCC); however, 20%–40% recur. Angiogenesis inhibitors have improved survival in 
metastatic patients and may result in responses in the neoadjuvant setting. The impact of these 
agents on the tumor genetic heterogeneity or the immune milieu is largely unknown. This phase 
II study was designed to evaluate safety, response, and effect on tumor tissue of neoadjuvant 
pazopanib.
METHODS. ccRCC patients with localized disease received pazopanib (800 mg daily; median 8 
weeks), followed by nephrectomy. Five tumors were examined for mutations by whole exome 
sequencing from samples collected before therapy and at nephrectomy. These samples underwent 
RNA sequencing; 17 samples were available for posttreatment assessment.
RESULTS. Twenty-one patients were enrolled. The overall response rate was 8 of 21 (38%). No 
patients with progressive disease. At 1-year, response-free survival and overall survival was 
83% and 89%, respectively. The most frequent grade 3 toxicity was hypertension (33%, 7 of 
21). Sequencing revealed strong concordance between pre- and posttreatment samples within 
individual tumors, suggesting tumors harbor stable core profiles. However, a reduction in private 
mutations followed treatment, suggesting a selective process favoring enrichment of driver 
mutations. 
CONCLUSION. Neoadjuvant pazopanib is safe and active in ccRCC. Future genomic analyses 
may enable the segregation of driver and passenger mutations. Furthermore, tumor infiltrating 
immune cells persist during therapy, suggesting that pazopanib can be combined with immune 
checkpoint inhibitors without dampening the immune response.
FUNDING. Support was provided by Novartis and GlaxoSmithKline as part of an investigator-
initiated study. 
2insight.jci.org   https://doi.org/10.1172/jci.insight.132852
C L I N I C A L  M E D I C I N E
Thus, although significant improvements have been made in the management of  metastatic disease, risk 
reduction at the point of  surgery is still an active area of  interest.
RCC has undergone a renaissance of  treatment strategies in the past decade, first with the introduction 
of  targeted therapies that have the potential to downsize tumors, delay disease progression, and markedly 
improve survival (5–7). In particular, therapies directed toward the VEGFR have consistently demonstrated 
promise in promoting reductions in tumor burden, thus providing a major mechanism for relief  of  pain and 
other tumor-related symptoms. Pazopanib, an oral angiogenesis inhibitor whose targets include VEGFR, the 
platelet-derived growth factor receptor (PDGFR), and c-Kit (8), received FDA approval for the treatment 
of  patients with advanced RCC based on a significant improvement in progression-free survival (PFS) com-
pared with placebo (9.2 months versus 4.2 months, P < 0.001), with an overall response rate (RR) of  30% (5).
A majority (88%) of  the patients enrolled on the randomized phase III trial that led to FDA approval 
of  pazopanib had prior nephrectomy, thus limiting the generalizability of  those results to the neoadjuvant 
setting. A recent study in patients with metastatic disease evaluated the safety and efficacy of  preoperative 
pazopanib, and it reported a 13% RR and 84% clinical benefit rate with manageable toxicities (9). Based 
on the demonstrated success in metastatic RCC, it is plausible that patients with locally advanced disease 
would also derive benefit from neoadjuvant pazopanib. Moreover, the second major breakthrough in the 
treatment of  RCC has been the introduction of  immune checkpoint blockade (ICB). ICB has broad indica-
tions in the treatment of  metastatic disease on the basis of  RR and overall survival data (10). Furthermore, 
combinations of  angiogenesis inhibitors with ICB are undergoing aggressive investigation (11–13). As ICB 
therapies are making their way into the perioperative setting, with major phase III clinical trials underway 
(14), it is essential to understand the potential effect of  angiogenic inhibitors to the tumor and the tumor 
microenvironment. Thus, we designed this phase II study to evaluate the safety and efficacy of  neoadjuvant 
pazopanib in patients with clinical stage II or greater localized disease.
As an exploratory objective, we described the association between specific molecular features of  RCC 
and tumor response. Clear cell type RCC (ccRCC) is a disease dominated by only a few high-frequen-
cy gene mutation events. Mutations in the von Hippel-Lindau (VHL) tumor suppressor are common, in 
combination with chromosome 3p loss of  heterozygosity (15). Mutations in several other 3p genes occur 
secondarily in SETD2, PBRM1, and BAP1, all identified via high-throughput sequencing studies (16–19). 
Genes such as TP53, PTEN, and mTOR are mutated in approximately 5% of  cases. The effect of  VEGF 
targeted therapy on the composition of  mutational clones within individual tumors is unknown. Theoret-
ically, resistant clones may become more apparent after treatment due to clonal selection. Therefore, we 
performed temporally separate tumor sequencing analyses in order to examine the effect of  treatment on 
the tumor mutational spectrum as a result of  exposure to pazopanib. We also examined pre- and posttreat-
ment tumors using RNA sequencing analysis to observe effects on the general transcript profile and tumor 
infiltrating immune signatures.
Results
Patient characteristics and study schema. Between July 2011 and October 2014, 21 patients were consent-
ed and enrolled. Baseline demographics and disease characteristics are listed in Table 1. The median 
age was 61 years (range:, 37–75 years), 86% (18 of  21) were male, and 62% (13 of  21) had hypertension 
at baseline. Tumors ranged in size from 3.4 cm to 11.7 cm in largest diameter, and a majority (52%) 
were stage IIIA. Eleven patients received treatment for 10–12 weeks, based on an initial schedule that 
called for 12 weeks of  drug treatment. No significant difference in response was observed for any of  
the demographic subgroups. The study was amended to allow 8 weeks of  treatment, due to challenges 
meeting target enrollment. One patient received only 6 weeks of  treatment due to dose interruption. 
Figure 1 depicts the study schema.
Efficacy. Of  the 21 patients enrolled, 8 achieved a partial response (PR) for a 38% RR. The other 13 
patients achieved stable disease (SD) by Response Evaluation Criteria in Solid Tumors (RECIST). Repre-
sentative imaging and histology of  5 patients is provided in addition to a graphical representation of  best 
response (Figure 2). The median reduction in tumor size after treatment was –22%; (range, –44% to  +7%). 
No difference in tumor response was observed between patients receiving 8–9 weeks of  treatment versus 
those treated for 10–12 weeks (P = 0.82). Representative histological sections before and after treatment 
are provided to demonstrate that substantial changes in the tumor histology were not observed. At 1 year, 
RFS was.83 (95% CI, 0.57–0.94) and OS was.89 (95% CI, 0.62–0.97). Treating urologists were asked to 
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comment on planned surgical approach before the start of  treatment, and the applied surgical procedure 
remained unchanged after treatment for all patients. The majority of  tumors were removed by radical 
nephrectomy (19 of  21), and 2 were removed by partial nephrectomy. Six patients underwent laparoscopic 
nephrectomy; the remainder were completed via an open approach.
Safety. Adverse events experienced by at least 3 patients are listed in Table 2. Most common treat-
ment-related toxicities were fatigue (71%), hypertension (57%), dysgeusia (52%), diarrhea (48%), nausea 
(43%), elevated aspartate aminotransferase (38%), elevated alanine aminotransferase (33%), and anorexia 
(33%) — the majority being grade ≤ 2. However, 7 patients experienced grade 3 hypertension, 2 patients 
had grade 3 elevated alanine aminotransferase, and 1 patient had grade 3 elevated aspartate aminotrans-
ferase. Other grade 3 events are listed in Table 2. No grade 4 or 5 treatment-related events were reported. 
No patients withdrew due to toxicity, although dose interruptions occurred for all grade 3 and bothersome 
grade 2 toxicities. Planned surgery was not delayed due to any pazopanib-related adverse events.
Molecular analysis of  allele frequency. Tumor specimens were collected before and after treatment using 
the schema outlined in Figure 1. High-throughput exon sequencing revealed an average of  190 muta-
tions (range, 100–240) in each tumor, which were recorded for each pre- and posttreatment specimen 
Table 1. Baseline characteristics (N = 21).
Data results





African American 2 (10%)
White 14 (66%)
Ethnicity, no. (%)
Hispanic or Latino 5 (24%)
Not Hispanic 16 (76%)
ECOG performance status, no. (%)
0 17 (81%)
1 4 (19%)
Hypertension at baseline, no. (%)
No 8 (38%)
Yes 13 (62%)
Diabetes at baseline, no. (%)
No 16 (76%)
Yes 5 (24%)




Clinical stage at baseline, no. (%)
 Stage II 4 (19%)
 Stage IIIA 11 (52%)
 Stage IIIB 2 (10%)
 Stage IIIC 2 (10%)
 Stage IV 2 (10%)




Sarcomatoid features, no. (%)
No 19 (90%)
Unknown 2 (10%)
ECOG, Eastern Cooperative Oncology Group.
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using the whole blood sample sequence as a reference. In order to confirm that significant differences at 
the level of  copy number gains and losses were not observed in the sample pairs due to either sampling 
effects or therapeutic exposure, we generated copy number features from the sequence read depths (Sup-
plemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.132852DS1). This highly concordant genome map indicates that the samples did not differ 
as clones at the level of  larger-scale copy number events. Further evidence is provided by the Kolmogor-
ov-Smirnov test of  distributions limited to the shared mutations. The lack of  significance for distributional 
differences in these shared mutations lends support that the significant differences seen in all mutations 
were not substantially affected by tumor cellularity.
Using an unsupervised clustering analysis, we observed complete pairing between pre- and post-
treatment (Figure 3A). This finding suggests that, in spite of  substantial differences in the mutations in 
any given sample, core mutations display a level of  consistency within the same tumor, even when the 
specimens are separated by distance, time, and treatment exposure.
Moreover, although the frequency varied between cases, the fraction of  private mutations was 
reduced in all of  the pairings in the posttreatment sample (Figure 3C). Private mutations are defined 
here as mutations that are uniquely observed in a single tumor sample and not shared by any other 
tumor sample from the same subject. This may suggest that there is a selective reduction in genet-
ic diversity in samples collected following treatment with pazopanib. The change in total mutation 
frequency between pre- and posttreatment for each sample is shown in Figure 3B. Density plots of  
the overall and private mutation profiles for the samples in aggregate demonstrate that the reduced 
diversity stems from reductions in private mutations, overall preserving the mutations that make up the 
shared set (Figure 3D). For each pair, we compared the pre- and posttreatment mutant allele frequency 
using a scatter plot method. It appears that the increases in mutant allele frequencies were largely driv-
en by exclusion of  private mutations (Supplemental Figure 2).
Transcriptome profile changes with neoadjuvant pazopanib therapy. In order to better understand the effect 
of  neoadjuvant pazopanib on the tumor and its microenvironment, we performed RNA sequencing of  
tumor specimens. A number of  genes were significantly upregulated and downregulated by neoadjuvant 
pazopanib (Figure 4, A and B). Genes with significantly increased expression after therapy included the 
Figure 1. Treatment and molecular biomarker analysis schema. Patients enrolled in this study were identified in the 
urological oncology clinic with nonmetastatic stage II or greater disease. All patients underwent a percutaneous biopsy 
to confirm clear cell histology and donated whole blood for genomic DNA comparison. Patients were treated with at 
least 8 weeks of pazopanib and evaluated by repeat imaging before nephrectomy. DNA was prepared for whole exome 
sequencing from the whole blood buffy coat, the pretreatment biopsy, and the posttreatment nephrectomy specimens. 
RNA was prepared for transcript analysis from pretreatment biopsy and nephrectomy specimen.
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metallothioneins MT1X and MT2A, a divalent cation transporter protein (SLC11A1); ERRFI1, G protein 
receptor genes that have been implicated in preventing cardiac hypertrophy (RGS2, RGS1); and GADD45B, 
a gene found to have increased expression with stress-induced growth arrest. Genes significantly downregu-
lated with pazopanib therapy included ENPP2 (autotaxin), which has been implicated in angiogenesis and 
tumor cell motility; the cadherin FAT3; and the kidney-enriched cytochrome monooxygenase CYP4A11. To 
evaluate whether gene expression patterns were consistent with activation of  specific biological processes, 
we performed gene set enrichment analysis (GSEA) (20). Gene sets with increased expression following 
neoadjuvant pazopanib included those associated with cellular stress responses (Figure 4, C and D).
Figure 2. Neoadjuvant treatment with pazopanib resulted in encouraging clinical activity in patients with treatment- 
naive, locally advanced clear cell RCC. (A) Representative examples of pre- and posttreatment CT images of a partial 
responder (left, patient [Pt.] 5) and a patient with stable disease (left, Pt. 6), respectively. RECIST v1.1 longest dimensions 
are shown in each panel. Changes in tumor density were not captured in response assessment. (B) Histology for each 
patient is shown. (C) Best percent change from baseline is shown for each patient, with the color scheme representing 
duration of neoadjuvant treatment. Dashed line is the RECIST v1.1–defined PR, showing 6 patients exhibited a PR on study. 
Additionally, the duration of neoadjuvant treatment has little effect on tumor regression.
 
6insight.jci.org   https://doi.org/10.1172/jci.insight.132852
C L I N I C A L  M E D I C I N E
Because ccRCC bears such a close association with hypoxia-induced transcript signatures, a specif-
ic analysis of  signatures linked with hypoxia signaling was undertaken (Supplemental Figure 3). Among 
common signatures of  hypoxia signaling, only a transcript signature of  migration and invasion was signifi-
cantly upregulated in the posttreatment tumor specimens (P < 0.005).
Stability of  immunogenomics features with neoadjuvant pazopanib therapy. We hypothesized that neoadjuvant pazo-
panib may elicit changes in the tumor immune microenvironment that would be evaluable via immunogenomics 
analysis. We did not find any immune gene signatures with significantly different expression comparing pre- and 
postpazopanib tumor gene expression (Figure 5). T cell receptor (TCR) repertoire diversity measured by the Shan-
non Entropy index showed some decreased diversity after treatment; however, the difference was not statistical-
ly significant due to diversity in a single patient increasing between pre- versus posttreatment (Figure 5B, blue 
points). There were also substantial differences in dominant and subdominant TCR clonotypes expressed, both 
within individual patients and between patients (Figure 5C). However, in 2 patient pairs after treatment, there was 
increased TCR clonotype sharing (i.e., the same clones present in both members of the pair) (Figure 5D).
Association of  transcriptome features with clinical response. We conducted an exploratory analysis to determine 
whether pretreatment gene expression or gene set enrichment was associated with clinical response. Compar-
ing the 2 outcomes in the study across the neoadjuvant time frame (SD or PR), the most significant differen-
tially expressed gene (FDR < 0.2) was the procadherin PCDHB5, which had increased expression in patients 
who achieved PR (Figure 6). Additionally, in light of  recent findings linking expression of  elements of  human 
endogenous retroviruses to response to checkpoint immunotherapy (21, 22), we examined the transcript data 
for evidence of  any such association, finding none.
Discussion
The role of  treatment with antiangiogenic agents, such as pazopanib, has been well established in patients 
with metastatic RCC. Therefore, it is plausible that neoadjuvant regimens would elicit similar benefit 
before nephrectomy and perhaps extend RFS. The aim of  this study was to evaluate the safety and efficacy 
of  neoadjuvant pazopanib in patients with localized, untreated ccRCC. Overall, neoadjuvant pazopanib 
was safe, with most treatment-related toxicities being grade ≤ 2. Frequency and severity of  toxicities were 
similar to those previously reported with pazopanib (5, 9, 23). Fatigue; hypertension; gastrointestinal tox-
icities, such as dysgeusia, diarrhea, and nausea; and elevated liver enzymes were most common adverse 
events and were manageable with conservative measures.
Table 2. Treatment-related adverse events reported in > 10% of patients (N = 21).
Adverse event All grades Grade 3A
Fatigue 15 (71%) 0
Hypertension 12 (57%) 7 (33%)
Dysgeusia 11 (52%) 0
Diarrhea 10 (48%) 0
Nausea 9 (43%) 0
Aspartate aminotransferase 
increased
8 (38%) 1 (5%)
Alanine aminotransferase increased 7 (33%) 2 (10%)




Vomiting 5 (24%) 0
Blood bilirubin increased 4 (19%) 0
Dizziness 4 (19%) 0
Hypothyroidism 4 (19%) 0
Oral dysesthesia 4 (19%) 0
Rash acneiform 3 (14%) 0
Skin hypopigmentation 3 (14%) 0
AOther related grade 3 events reported in 1 patient each were: Alkaline phosphatase increased, GGT increased, 
hepatobiliary disorder, and hyponatremia. No treatment-related grade 4 or 5 events were observed.
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Neoadjuvant pazopanib resulted in 8 tumor PRs (38%, 8 of 21). Responses observed in this study are simi-
lar to the study from Rini et al. that reported a 36% RR in patients with localized ccRCC who underwent 8–16 
weeks of neoadjuvant pazopanib (23). Furthermore, these observed responses were similar to that reported in 
the phase III randomized study (30% RR by independent review) that led to pazopanib approval for patients 
with metastatic disease (5). Collectively, these results suggest that neoadjuvant pazopanib is just as effective for 
the treatment of patients with localized ccRCC.
No significant difference in response was observed, despite patients receiving drug over a time ranging 
from 8 to 12 weeks, although the optimal duration remains unknown. These findings were consistent with 
the findings of  Rini et al., which reported that most of  the substantial responses that changed surgery from 
radical to partial nephrectomy was observed after 8 weeks (23). However, the limitations of  the current 
and previous neoadjuvant studies highlight the fact that the clinical utility of  neoadjuvant pazopanib will 
need further evaluation in larger, prospective cohorts — ideally, randomized studies that evaluate clinical 
outcomes of  neoadjuvant pazopanib followed by nephrectomy versus nephrectomy alone. Nonetheless, neo-
adjuvant treatment with pazopanib is effective at reducing tumor size, potentially leading to less complicated 
surgical approaches in patients with localized ccRCC.
This study, which consisted of  molecular analyses, identified strong intratumoral correlations in the 
mutational spectrum of  prepazopanib-treated and postpazopanib-treated specimens. This consistent muta-
tional pattern of  exclusion of  private mutations and enrichment of  the driven genes seen in the paired 
Figure 3. Results of the DNA allelic frequency analysis. (A) Hierarchical cluster analysis of mutations from pre- to posttreatment samples reveals close 
clustering of corresponding pre- and posttreatment samples. Each tumor is annotated along x axis. MAF, mutant allele frequency. (B) Overall total 
mutations are decreased in posttreatment tumors. (C) The number of private mutations for each sample was divided by the overall number of mutations 
between the pairs to yield the fraction of private mutations: a reflection of increasing clonality in the post-treatment tumors. (D) Density plots comparing 
all mutations with shared mutations only (private mutations excluded) shows that differences between samples are due to private mutations.
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biopsies has a vanishingly low random probability. Indeed, the 5 cases with paired samples cluster together. 
This finding does not contradict the heterogeneity studies previously reported (24, 25). While tumor hetero-
geneity exists in both models, our examination of  tumor specimens separated by time, space, and treatment 
exposure indicates that these factors have the potential to influence the mutation spectrum of  a tumor.
Treatment appeared to enrich for relevant mutations commonly associated with RCC. The majority of  
tumors demonstrated a reduction in overall mutation number and an increase in mutant allele frequency, 
rather than evidence for adaptations that increase heterogeneity through further mutation or other genomic 
instability. Whether this adaptation involves a selective elimination of  cells bearing passenger mutations, 
or an enrichment for a clonally derived set of  tumor cells, it would appear that the exposure to a relatively 
short period of  anti-VEGFR therapy selects for a unique set of  tumor cells in each tumor. It cannot be 
determined if  this reflects sensitivity to therapy of  a specific tumor cell subset or a feature of  emergent 
resistance — only that the mutations identified in the posttreatment sample remain relevant and are not 
indicative of  the expansion of  a highly heterogeneous tumor cell pool. A third tumor biopsy at clinically 
apparent resistance would be required to answer this question.
The concept that tumor selection can enrich for important driver mutations is not new in RCC. 
Recently, Peña-Llopis et al. demonstrated that tumor cells grown as patient-derived xenografts enriched 
Figure 4. Transcriptional changes with neoadjuvant pazopanib therapy. (A) DESeq2 was used to perform differential 
gene expression analysis on unnormalized gene counts from patients before and after pazopanib treatment. Heatmap 
shows z scores of genes significantly different after Benjamini-Hochberg FDR correction (P ≤ 0.2) ordered by fold 
change. (B) Volcano plot shows all DESeq2 gene results, graphing P value over change. Color indicates FDR corrected 
P value of gene. The 20 most significant genes are labeled. (C) Single-sample gene set enrichment analysis (ssGSEA) 
was performed on upper-quartile normalized gene expression data from patients in A. The primary gene sets used 
were MSigDB’s chemical and genetic perturbations, KEGG, and oncogenetic signatures. As in A, z scores of gene sets 
significantly different (FDR-corrected P ≤ 0.2) are shown. (D) All ssGSEA gene sets from analysis in C are shown with 
the highest 20 genes sets labeled.
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sufficiently to allow the discovery of  BAP1 as a leading driver mutation (17). The process of  tumor sur-
vival in the setting of  VEGF-targeted therapy exerts a different but similar set of  external forces, which 
may also enrich for aggressive clonal subsets. Pazopanib therapy may similarly favor the expansion of  
clones, possibly owing to the altered extracellular environment or depletion of  oxygen and nutrient 
resources, resulting in the enrichment of  clones. This may be explained by the increased mutation allele 
frequency, through a selective exclusion of  a subset of  the tumor cells, thus eliminating the noise of  
highly variable passenger mutations.
We show that neoadjuvant pazopanib led to decreased genetic diversity via a contraction of  tumor 
clonotypes recovered from whole exome sequencing (Figure 3). Additionally, although the T cell con-
tent was slightly reduced, we do not have sufficient data to imply that this reflects T cell repertoire 
restriction in response to treatment. In a recent analysis of  genomics data from melanoma patients 
treated with PD-1 inhibition (nivolumab), genomic contraction on therapy was significantly associated 
Figure 5. Immune features pre and post neoadjuvant pazopanib therapy. (A) Immune gene signatures were made 
from log2 normalized gene counts. Two-tailed t test comparisons were made between matched patient pre- and post-
treatment samples. No signatures were significant after Benjamini-Hochberg FDR correction. (B) Shannon entropy was 
calculated on TRB CDR3 counts. Points are colored by patient. Pre- and posttreatment results were not significantly 
different (paired t test, P = 0.18). (C) Public IgH CDR3 are represented on the y axis. Heatmap colors indicate the fraction 
of total counts a CDR3 represents out of the total IgH CDR3 counts for each a sample. (D) Morisita-Horn index was 
calculated on the fractional expression of all IgH CDR3 for each sample combination.
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with achievement of  partial or complete response (26). In non–small cell lung cancer, tumor genetic 
heterogeneity was associated with primary resistance to immune checkpoint inhibition (27). Future 
studies using single cell analysis will be necessary to address this issue directly. Finally, while we 
do not hypothesize that pazopanib works primarily through an immunological mechanism, should a 
relationship between genetic homogeneity and response be confirmed, neoadjuvant therapy may be an 
effective venue for combination treatments of  VEGF receptor TKI with immune checkpoint inhibition 
and should be evaluated further.
Ultimately, this exploratory study provides information on 2 aspects of  RCC tumor genome biol-
ogy. First, samples within a tumor, even temporally separated by a therapeutic intervention, cluster 
together, revealing that each tumor has a fairly unique profile of  mutations that separates it from 
other tumors with similar histological features. Therefore, biomarker research to define tumors using 
discrete specimens is not futile (28), despite the presence of  tumor heterogeneity. Second, this explor-
atory analysis revealed that genomic heterogeneity is reduced within samples following treatment with 
VEGF-targeted therapy, suggesting an alteration in the process of  clonal evolution with elimination 
of  specific tumor cell subsets sensitive to treatment. The posttreatment tumor may therefore be more 
representative of  the clones responsible for driving the cancer or more relevant to the disease process. 
Genetic biomarker analysis after a specific period of  targeted therapy should be considered as medical 
practice moves toward personalized therapy.
This study had several limitations. Given the small sample size, it is difficult to compare the fre-
quency of  common driver mutations to larger data sets. In addition, the small size of  the biopsy sam-
ples, obtained by core biopsy, expose the specimens to spatial heterogeneity. Second, the low frequency 
of  VHL mutations in our set may seem surprising in light of  the high frequency of  these mutations that 
is seen in some series. However, our methodologies do not capture hypermethylation as a cause of  VHL 
inactivation, and in the many large data sets, the combined VHL mutation and methylation frequency 
is just over 50% (29). Nonetheless, we were able to find statistically and clinically significant findings.
In conclusion, our results, albeit in a small sample, suggest that neoadjuvant pazopanib is safe 
and efficacious to produce tumor reduction in ccRCC patients who are treatment naive and have 
localized disease. Additionally, exploratory genomic analyses showed that the majority of  tumors 
demonstrated a reduction in overall mutation number and an increase in mutant allele frequency 
without altering immune expression signatures substantially, providing evidence for further investiga-
tion of  specific genetic biomarkers of  tumor response.
Figure 6. Transcriptional changes with neoadjuvant pazopanib therapy. DESeq2 was used to perform differential gene expression analysis on unnormal-
ized gene counts between pretreatment samples of patients (n = 15) showing stable disease and patients (n = 6) showing partial response to pazopanib 
treatment. Volcano plot shows all DESeq2 (R package v1.14.1; ref. 38) gene results, graphing P value over fold change. Color indicates FDR-corrected P value 
of gene. The 20 most significant genes are labeled. (A and B) Typical non-hERV encoding genes (A) and hERV genes (B).
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Methods
Study design and patient selection
This multiple-institution, single-arm phase II study (NCT01361113) investigated neoadjuvant pazopanib 
in patients with localized ccRCC. Pazopanib was orally administered in 800 mg once-daily doses for 8–12 
weeks, followed by nephrectomy. Adult patients with localized ccRCC, radiological evidence of  nonmeta-
static disease, and were appropriate candidates for nephrectomy were eligible. A complete set of  eligibility 
criteria is provided in the Supplemental Data. Patients were required to have a performance status of  0 or 1 
with adequate organ function and no known coagulopathy. Patients who had a known or suspected allergy 
to pazopanib, were unable to swallow oral medication, were pregnant or breastfeeding, or had a history of  a 
cerebrovascular accident or cardiovascular condition within 6 months of  starting pazopanib were excluded. 
Other eligibility criteria are included in the Supplemental Data.
Imaging was performed on all patients before therapy and before nephrectomy; the primary endpoint 
of  tumor response was measured using RECIST 1.1 (30).
Laboratory correlatives
Tissue and blood samples. In consenting patients, tissue biopsies were performed before starting treatment and 
from nephrectomy specimens. Tissue cores were flash frozen and stored in liquid nitrogen. Whole blood 
was also collected for genomic studies.
Genomic analysis and transcriptional analysis. Samples from the pretreatment and postnephrectomy biop-
sies were divided for immediate snap freezing or formalin fixation, followed by processing using a standard 
tissue processor (Leica Peloris II) and paraffin embedding. Five micron-thick sections were stained with 
H&E for light microscopic evaluation. Images from these diagnostic slides were prepared at 40× magnifica-
tion on a Leica digital imaging microscope using standard bright-field settings.
Samples were processed for DNA from pulverized frozen tissue or whole blood buffy coat using QIA-
GEN genomic DNA isolation products. DNA was fragmented by sonication, and libraries were prepared 
using Nextera Rapid Exome Capture (Illumina). The samples were run on Illumina 2500 HiSeq, using 
100 bp paired end reads. Alignment to hg19 was performed using the BWA “mem” algorithm (available at 
https://github.com/lh3/bwa). Primary alignments were then realigned using ABRA (31); somatic variants 
were called using Strelka (32) and were annotated with SnpEff  (33). False negatives could greatly influence 
our inference regarding the frequency and nature of  private mutations. Thus, we chose to limit false neg-
atives by first selecting all mutations called with high confidence (Strelka QSS_NT>30 or QSI_NT>30) in 
any 1 sample from a subject. The union set from all samples of  a subject was then used to query the data and 
estimate the mutant allele frequency for all samples of  a subject. In this way, any evidence (reads) supporting 
a mutation in both pre- and posttreatment samples was used even if  a high-quality mutation call exits in 
only one of  the pair. The resulting matrix of  mutant allele frequencies were characterized with hierarchi-
cal clustering (Euclidean distance, complete linkage), and distributions were compared visually with quan-
tile-quantile plots. Private mutations are defined here as mutations that are uniquely observed in a single 
tumor sample and not shared by any other tumor sample from the same subject. A Kolmogorov-Smirnov 
test was performed to test the null hypothesis that the distribution of  mutant allele frequencies was not dif-
ferent between the pre- and posttreatment samples. Differences could be due to change in tumor cellularity 
or clonality. In order to control for differences in tumor cellularity, the same test was performed using only 
mutations with frequency greater than zero in both samples.
The whole exome data were used to calculate allele frequencies using the DNAcopy package in R and 
present as copy number for comparison between pre- and posttreatment. Although pretreatment biopsy was 
a requirement for enrollment, only 5 of  the subjects had pretreatment biopsies of  sufficient quantity and 
quality for nucleic acid assessment.
Transcriptional analysis. Samples were processed for RNA from pulverized frozen tissue using QIAGEN 
RNA isolation products. RNA was quantified using Qubit, and quality was assured using NanoDrop to 
assess potential contamination and TapeStation to assess fragment size. RNA sequencing libraries were 
prepared using the Illumina TruSeq stranded protocol, and sequencing was done using the Illumina HiS-
eq2500 platform with 2 × 75 paired end chemistry. Output Fastq files were assessed for sequencing read 
quality using the FASTQC software (34), and Fastq files were aligned to the hg38 transcriptome with STAR 
(v2.4.2a) (35) and assembled with Salmon (v0.6.0) (36). Samples with fewer than 30 million multimapped 
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and uniquely mapped reads were dropped from further analysis. Genes were converted from UCSC format 
to HGNC symbols and Entrez IDs using the R package biomRt (37). Differential gene expression was done 
using the R package DESeq2 (v1.14.1) (38) on the unnormalized gene output. GSEA was performed on 
upper quartile normalized gene counts using the single-sample GSEA (ssGSEA) method in the R package 
GSVA (v1.22.4) (39). Most gene sets came from Molecular Signatures Database’s (MSigDB’s) chemical 
and genetic perturbations (https://www.gsea-msigdb.org/gsea/msigdb/), KEGG (https://www.genome.
jp/kegg/pathway.html), oncogenetic signatures (40), and previously curated immune gene signature gene 
sets (41–50). All next-generation sequencing data have been deposited in a MINSEQE-compliant public 
database (dbGap; accession hon. phs002053.v1.p1; https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?study_id=phs002053.v1.p1).
Statistics
The overall RR was calculated and reported, along with its exact 95% CI. The Kaplan-Meier method was used 
to estimate RFS and OS, and their estimates at 1 year — along with their 95% CIs — have been reported. RFS 
has been calculated using the time from the start date of treatment until the date of documented disease recur-
rence (as defined via RECIST1.1), to the date of death from any cause, or to the date of last contact (censored). 
OS has been calculated using the time from the start date of treatment to the date of death from any cause or the 
date of last contact (censored). The Wilcoxon rank sum test was used for 2-group comparisons. The Kolmogor-
ov-Smirnov test was used to compare distributions. The 2-tailed, paired t test was used to make within-patient 
pre- to posttreatment comparisons. The Benjamini-Hochberg FDR method was used to adjust for multiple test-
ing. Toxicity assessments were graded according to the NCI Common Toxicity Criteria, version 4.0 (CTCAE 
v4), and were reported as percentages of the highest grade toxicity, per toxicity, per patient. Reported P values 
were 2 sided, with P < 0.05 considered statistically significant. Statistical analyses were performed with SAS 
statistical software, version 9.2, and R: A language and environment for statistical computing (R Foundation 
for Statistical Computing; ISBN 3-900051-07-0; http://www.R-project.org/). The Morisita-Horn index was 
used to compare the similarity of adaptive immune receptor repertoires between samples. This similarity index 
incorporates the number of shared clonotypes, as well as the relative dominance of shared clonotypes, and it is 
thus well suited to adaptive immune receptor repertoire data. The Morisita-Horn index values were calculated 
using the “horn” method of the R function vegan::vegdist (https://CRAN.R-project.org/package=vegan).
Study approval
This clinical trial was approved by the IRBs at the University of  Carolina at Chapel Hill (Office of  Human 
Research Ethics) and MD Anderson (Office of  Human Subjects Protection), and the research was conduct-
ed according to the Declaration of  Helsinki principles. All participants provided written informed consent 
before the initiation of  any research procedures.
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